Journal List > Korean J Schizophr Res > v.16(1) > 1057786

Korean J Schizophr Res. 2013 Apr;16(1):14-24. Korean.
Published online April 30, 2013.
Copyright © 2013 Korean Society for Schizophrenia
The Preference Survey for Long-Acting Injectable Antipsychotics of Community-Dwelling Patients with Schizophrenia and their Caregivers
Yoong Lee, MD,1 Nam-Young Lee, MD, PhD,1 Tak Youn, MD, PhD,1 Yong-Seoung Choi, MD, PhD,2 Yong-Sik Kim, MD, PhD,1 and In-Won Chung, MD, PhD1
1Department of Neuropsychiatry and Institute of Clinical Psychopharmacology, Dongguk University International Hospital, Goyang, Korea.
2St. Andrew's Neuropsychiatric Hospital, Icheon, Korea.

Address for correspondence: In-Won Chung, Department of Neuropsychiatry and Institute of Clinical Psychopharmacology, Dongguk University International Hospital, 814 Siksa-dong, Ilsandong-gu, Goyang 410-773, Korea. Tel: 031-961-7231, Fax: 031-961-7230, Email:
Received December 12, 2012; Revised December 26, 2012; Accepted January 09, 2013.



The prescription rates of long-acting injectable (LAI) antipsychotics are very low around 1% in Korea. This study was aimed to explore the preference of LAIs in patients with schizophrenia, who are currently living in community, and their caregivers.


The patients, diagnosed with schizophrenia by DSM-IV TR and were registered in the 31 mental health centers of Gyeonggi province and their caregivers were inquired the knowledge of the LAIs. The questionnaires contained information such as demographic characteristics, history of psychiatric treatment, and so on.


About 5,318 were registered in 31 community mental health centers of Gyeonggi province in February 2012. The questionnaires of 614 patients and 365 caregivers were gathered from 20 community mental health centers. The mean ages (±SD) of patients and caregivers were 41.9 (±10.2) and 62.2 (±13.4) years old, respectively. 272 patients (44.6%) had experienced the discontinuation of medications without doctor's consent. 217 patients (35.9%) and 97 caregivers (27.1%) knew about the LAIs. The preference rates for LAIs were 35.2% and 46.8% for the patients and caregivers, respectively.


There is still huge discrepancy between the preference and the real prescriptions of LAIs in community-dwelling patients and their caregivers, much higher than in those of hospital settings. This study suggests that both patients and caregivers registered in the community mental health centers have a strong commitment to live in the community. The obstacles against the benefits of LAIs need to be resolved.

Keywords: Schizophrenia; Long-acting injectable antipsychotics; Community mental health centers


Table 1
Age and sex in patients with schizophrenia and their caregivers
Click for larger image

Table 2
Clinical characteristics and medication history of patients with schizophrenia
Click for larger image

Table 3
Attitude of patients with schizophrenia and caregivers on antipsychotic long-acting injections (LAIs)
Click for larger image

Table 4
Comparison of clinical characteristics of patients and caregivers respectively on their preferences toward long-acting injections (LAIs) to oral antipsychotics
Click for larger image


Dr. YS Kim received grants, research support and honoraria from AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Organon, Otsuka, Sanofi-Aventis and Servier. Dr. IW Chung received research supports from Bukwang Pharm. Co. LTD., CJ CheilJedang Corp., Janssen, Lundbeck, and MSD. Dr. T Youn received research supports from Bukwang Pharm. Co. LTD., CJ CheilJedang Corp., Janssen, and MSD. Dr. NY Lee received research supports from CJ CheilJedang Corp., Janssen, and MSD. Other authors have no financial conflict of interest.

1. Hong JP, Hwang SC, Lee YM, Lee SH, Shin NL, Lee JI, et al. Community Psychiatry Training for Psychiatry Residents. J Korean Neuropsychiatr Assoc 2008;47:88–93.
2. Harvey CA, Jeffreys SE, McNaught AS, Blizard RA, King MB. The Camden Schizophrenia Surveys III: five-year outcome of a sample of individuals from a prevalence survey and the importance of social relationships. Int J Soc Psychiatry 2007;53:340–356.
3. WHO-AIMS report on mental health system in republic of Korea. WHO, Ministry of Health & Welfare, Republic of Korea; 2007.
4. National report for the protection and improvement of the rights of person with mental illness. National Human Rights Commission of Korea; 2009.
5. Lee MS, Hong JP, Ko JA, Oh JH. Follow-Up Survey of Discharged Patients by the Mental Health Review Board. J Korean Neuropsychiatr Assoc 2009;48:42–47.
6. Schennach R, Obermeier M, Meyer S, Jäger M, Schmauss M, Laux G, et al. Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv 2012;63:87–90.
7. Osborne RH, Dalton A, Hertel J, Schrover R, Smith DK. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual Life Outcomes 2012;10:35.
8. Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 2004;65:120–131.
9. McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leal R, Rössler W, et al. The therapeutic relationship and adherence to antipsychotic medication in schizophrenia. PLoS One 2012;7:e36080.
10. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107–117.
11. Lambert T, de Castella A, Kulkarni J, Ong A, Singh B. One year estimate of depot antipsychotic adherence and readmission in Australian community mental health settings. Schizophr Bull 2007;33:485.
12. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83–92.
13. Viala A, Cornic F, Vacheron MN. Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia. Schizophr Res Treatment 2012;2012:368687.
14. Lambert T, Olivares JM, Peuskens J, Desouza C, Kozma CM, Otten P, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011;10:10.
15. Spill B, Konoppa S, Kissling W, Maino K, Messer T, Heres S. Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract 2010;14:53–62.
16. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC psychiatry 2010;10:2.
17. Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1231–1235.
18. Kim SW, Yoon JS. A Survey on Attitudes of Korean Psychiatrists Toward Long-Acting Injectable Antipsychotics: An Interim Analysis. Korean J Psychopharmacol 2011;22:S10–S17.
19. Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study. Clin Schizophr Relat Psychoses 2012;6:61–68.
20. Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl 2009;52:S37–S42.
21. Kang G, Kang S, Yoon H, Lee J. Attitudes of patients with schizophrenia and their caretakers toward treatment with long-acting injectable antipsychotic medication. J Korean Assoc Soc Psychiatry 2010;15:67–73.
22. Sunwoo YK, Kim JY, Bae JN, Kim CE. A female patient with schizophrenia treated with risperdal consta during the entire period of pregnancy. Korean J Psychopharmacol 2006;17:573–575.
23. Youn T. A Case of Aggressive and Violent Patient with Treatment-Resistant Schizophrenia Treated with Long-Acting Injectable Risperidone. Korean J Psychopharmacol 2007;18:171–176.
24. Park H, Bae S, Ryoo J, Kim S, Lim W. Attitudes of Korean psychiatrists toward treatment long-acting injectable antipsychotic. J Korean Neuropsychiatr Assoc 2009;48:182–189.
25. Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64:5–19.
26. Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072–2082.
27. West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008;34:995–1001.
28. Health Insurance Review & Assessment: 2012.
29. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692–699.
30. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892–909.
31. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–1223.
32. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637–651.
33. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 2004;65:531–536.
34. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260–267.
35. Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, et al. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007;40:257–263.
36. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247–256.
37. Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022–1031.
38. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010;13:635–647.
39. Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235–244.
40. Gopal S, Pandina G, Lane R, Nuamah I, Remmerie B, Coppola D, et al. A Post-hoc Comparison of Paliperidone Palmitate to Oral Risperidone During Initiation of Long-acting Risperidone Injection in Patients with Acute Schizophrenia. Innov Clin Neurosci 2011;8:26–33.
41. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218–226.
42. Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1002–1008.
43. Llorca PM, Miadi-Fargier H, Lancon C, Jasso Mosqueda G, Casadebaig F, Philippe A, et al. Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encephale 2005;31:235–246.
44. Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Ann Clin Psychiatry 2007;19:65–71.
45. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008;30:2378–2386.
46. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008;28:210–213.
47. Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007;21:441–448.
48. Franz M, Ranger J, Hanewald B, Gallhofer B, Lay B. Influences on Therapist's Decisions for Neuroleptic Treatment in Schizophrenia: The Role of Characteristics of the Patient and the Physician. Pharmacopsychiatry 2012;45:261–268.
49. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007;22:275–282.
50. Jeong IW, Hyun MH, Kim JW, Bae JN, Jang HS, Na DS, et al. In: National Human Rights Commission of the Republic of Korea; 2008. pp. 25.
51. Park JI, Jang HS, Lee JS, Lee MS. In: The structural causes and maintenance factors affecting long-term hospitalization. National Human Rights Commission of the Republic of Korea; 2008.
52. Bettoni M, Benigni B. Italian Law 180: the enduring principles it represents and the community of Arezzo. Ann Ist Super Sanita 2009;45:17–21.